Compare State Street Corporation Common Stock (STT) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
State Street Corporation Common Stock vs Tango Therapeutics Inc. — how do they compare? State Street Corporation Common Stock trades at $166.95 (market cap $47.83B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: State Street Corporation Common Stock is far larger — about 12.8× Tango Therapeutics Inc.'s market cap, and State Street Corporation Common Stock pays a 2.11% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold State Street Corporation Common Stock for 2 Days and Tango Therapeutics Inc. for 0 Days on average.
| STT | TNGX | |
|---|---|---|
Market Cap | $47.83B | $3.75B |
Volume | 2,907,463 | 9,619,106 |
Sector | Financials | Health |
52-Week High | $194.26 | $32.90 |
52-Week Low | $111.37 | $7.50 |
Typical Hold Time | 2 Days | 0 Days |
Enterprise Value | $74.34B | $2.77B |
Dividend Yield | 2.11% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
State Street (STT) trades at $173.99, down 0.54% with bearish technical signals despite strong Q3 2026 earnings beat. The stock faces headwinds from a revenue miss and ongoing investigation, though fundamentals show robust profitability with 22.95% net margin and consistent earnings growth. Analyst consensus remains positive with $183.55 price target, but technical indicators show selling pressure with support at $172.
Outlook is mixed with strong fundamentals supporting long-term value, but near-term risks from the securities investigation and bearish technicals create uncertainty. The 13% revenue growth and record AUM provide upside potential, though investors should monitor legal developments and expense trends that could impact sentiment.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About State Street Corporation Common Stock
State Street provides investment servicing, custody, and asset management services to institutional investors. Its asset management business includes the SPDR ETF range.
Read more on STT →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
